Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of OXP005 vs Naprosyn in Healthy Adults
NCT02351024Phase 1Completed
- Sponsor
- Oxford Pharmascience
- Start
- Feb 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of OXP005 in rheumatic disease and pain (2 arms), sponsored by Oxford Pharmascience. Primary endpoints: Time to Maximum Plasma Concentration at Day 8, Maximum Plasma Concentration at Day 8 and 2 more. Started Feb 2015; status: completed.
02
Drugs
OXP005
03
Conditions
rheumatic diseasepain
Beyond the preview
Go deeper on NCT02351024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351024.